DRW Securities LLC Invests $392,000 in Exelixis, Inc. (NASDAQ:EXEL)

DRW Securities LLC acquired a new position in Exelixis, Inc. (NASDAQ:EXEL) in the second quarter, Holdings Channel.com reports. The fund acquired 17,425 shares of the biotechnology company’s stock, valued at approximately $392,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Fisher Asset Management LLC boosted its holdings in Exelixis by 232.6% in the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 728 shares in the last quarter. Rise Advisors LLC acquired a new stake in Exelixis in the 1st quarter worth approximately $28,000. Park Place Capital Corp acquired a new stake in Exelixis in the 2nd quarter worth approximately $45,000. GAMMA Investing LLC grew its position in Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 1,041 shares during the last quarter. Finally, EntryPoint Capital LLC increased its stake in Exelixis by 537.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,746 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Stock Performance

Shares of Exelixis stock opened at $26.36 on Tuesday. The firm has a 50-day simple moving average of $25.28 and a two-hundred day simple moving average of $23.38. Exelixis, Inc. has a fifty-two week low of $18.64 and a fifty-two week high of $27.83. The company has a market cap of $7.99 billion, a P/E ratio of 41.19, a price-to-earnings-growth ratio of 0.58 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.44. The firm had revenue of $637.18 million during the quarter, compared to analyst estimates of $468.21 million. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. Equities research analysts forecast that Exelixis, Inc. will post 1.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Truist Financial reiterated a “buy” rating and set a $33.00 price objective (up from $32.00) on shares of Exelixis in a research note on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a report on Wednesday, September 18th. Oppenheimer restated an “outperform” rating and issued a $29.00 price objective on shares of Exelixis in a research note on Tuesday, July 30th. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $27.00 price target on shares of Exelixis in a report on Wednesday, August 7th. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Exelixis has an average rating of “Moderate Buy” and a consensus price target of $27.67.

Insider Transactions at Exelixis

In other news, EVP Dana Aftab sold 95,000 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the transaction, the executive vice president now owns 520,990 shares in the company, valued at approximately $13,024,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Maria C. Freire sold 8,250 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total transaction of $219,120.00. Following the completion of the transaction, the director now owns 91,007 shares in the company, valued at approximately $2,417,145.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Dana Aftab sold 95,000 shares of Exelixis stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total value of $2,375,000.00. Following the completion of the sale, the executive vice president now owns 520,990 shares in the company, valued at $13,024,750. The disclosure for this sale can be found here. Insiders sold a total of 302,858 shares of company stock valued at $7,980,629 in the last three months. 2.85% of the stock is currently owned by company insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.